Acute heart failure volume control multicenter randomized (AVCMA) trial: Comparison of tolvaptan and carperitide
| Autor: | Isao Kubota, Yasuchika Takeishi, Akiomi Yoshihisa, Kazuhiko Nakazato, Shu-ichi Saitoh, Takayoshi Yamaki, Takayuki Ohwada, Tomiyoshi Saito, Koichi Sugimoto, Hiroyuki Kunii, Yukihiko Abe, Hitoshi Suzuki, Satoshi Suzuki |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
medicine.medical_specialty acute decompensated heart failure Acute decompensated heart failure Tolvaptan Diuresis Volume control Sodium excretion Cardiovascular Disorder Internal medicine volume control Humans Medicine carperitide Pharmacology (medical) Diuretics Intensive care medicine Aged Aged 80 and over Heart Failure Pharmacology tolvaptan business.industry Original Articles Benzazepines Middle Aged medicine.disease Heart failure Acute Disease Cardiology Female business Hyponatremia Antidiuretic Hormone Receptor Antagonists Atrial Natriuretic Factor medicine.drug |
| Zdroj: | Journal of Clinical Pharmacology |
| ISSN: | 1552-4604 0091-2700 |
| Popis: | Backgroud Acute decompensated heart failure (ADHF) is a common and highly morbid cardiovascular disorder. Diuresis is a major therapy for the reduction of congestive symptoms. However, most diuretics cause hyponatremia, which is a worsening factor of ADHF patients prognosis. The purpose of this study was to examine the efficacy and safety of tolvaptan, which is a selective vasopressin V2 receptor antagonist and produces water excretion without changes in sodium excretion, compared with carperitide. Methods and Results One hundred and nine hospitalized ADHF patients were enrolled and randomly assigned to tolvaptan or carperitide treatment groups. Subjective symptoms and plasma BNP level were similarly improved by treatment in both groups. Urine volume was significantly higher in the tolvaptan group (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text